Commerzbank set a €100.00 ($116.28) price objective on Merck KGaA (FRA:MRK) in a report published on Wednesday. The brokerage currently has a buy rating on the healthcare company’s stock.

Several other equities analysts have also weighed in on MRK. Sanford C. Bernstein set a €105.00 ($122.09) price objective on shares of Merck KGaA and gave the company a buy rating in a research report on Thursday, August 9th. Kepler Capital Markets set a €106.00 ($123.26) price objective on shares of Merck KGaA and gave the company a buy rating in a research report on Thursday, August 9th. UBS Group set a €115.00 ($133.72) price objective on shares of Merck KGaA and gave the company a buy rating in a research report on Thursday, August 9th. Finally, Berenberg Bank set a €104.00 ($120.93) price objective on shares of Merck KGaA and gave the company a buy rating in a research report on Thursday, August 9th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and seven have given a buy rating to the company’s stock. Merck KGaA has a consensus rating of Hold and a consensus price target of €98.00 ($113.95).

FRA MRK opened at €97.64 ($113.53) on Wednesday. Merck KGaA has a 52-week low of €76.60 ($89.07) and a 52-week high of €115.00 ($133.72).

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Featured Article: Debt-To-Equity Ratio

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.